David Game

ORCID: 0009-0005-6556-0003
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Renal Transplantation Outcomes and Treatments
  • T-cell and B-cell Immunology
  • Immune Cell Function and Interaction
  • Kidney Stones and Urolithiasis Treatments
  • Biomedical Research and Pathophysiology
  • Pediatric Urology and Nephrology Studies
  • Organ Transplantation Techniques and Outcomes
  • Organ Donation and Transplantation
  • CAR-T cell therapy research
  • Biomedical Ethics and Regulation
  • COVID-19 Clinical Research Studies
  • Psychosomatic Disorders and Their Treatments
  • Immunotherapy and Immune Responses
  • Family Caregiving in Mental Illness
  • Methemoglobinemia and Tumor Lysis Syndrome
  • Organ and Tissue Transplantation Research
  • Neonatal Health and Biochemistry
  • Renal Diseases and Glomerulopathies
  • Ureteral procedures and complications
  • Urological Disorders and Treatments
  • Chronic Kidney Disease and Diabetes
  • Mental Health Treatment and Access
  • Healthcare cost, quality, practices
  • Modernist Literature and Criticism
  • Metabolism and Genetic Disorders

Guy's Hospital
2006-2024

Guy's and St Thomas' NHS Foundation Trust
2013-2024

St Thomas' Hospital
2015-2023

Chelsea and Westminster Hospital
2020

Park University
2020

Seattle University
2020

Microsoft (Brazil)
2020

Lister Hospital
2019

King's College London
2005-2011

Imperial College Healthcare NHS Trust
2009

Katie Wong David Pitcher Fiona Braddon Lewis Downward Retha Steenkamp and 95 more Nicholas M. P. Annear Jonathan Barratt Coralie Bingham Constantina Chrysochou Richard J. Coward David Game Siân Griffin Matt Hall Sally Johnson Durga Kanigicherla Fiona Karet Frankl David Kavanagh Larissa Kerecuk Eamonn R. Maher Shabbir H. Moochhala Jenny Pinney John A. Sayer Roslyn Simms Smeeta Sinha Shalabh Srivastava Frederick W.K. Tam Andrew Neil Turner Stephen B. Walsh Aoife Waters Patricia D. Wilson Edwin K.S. Wong C. Mark Taylor Dorothea Nitsch Moin A. Saleem Detlef Böckenhauer Kate Bramham Daniel P. Gale Sharirose Abat Shazia Adalat Joy O. Agbonmwandolor Zubaidah Ahmad Abdulfattah Alejmi Rashid Almasarwah Nicholas M. P. Annear Ellie Asgari Amanda Ayers Jyoti Baharani Gowrie Balasubramaniam Felix Kpodo Tarun Bansal Alison Barratt Jonathan Barratt Megan Bates N K Bayne Janet Bendle Sarah Benyon Carsten Bergmann Sunil Bhandari Coralie Bingham Preetham Boddana Sally L. Bond Fiona Braddon Kate Bramham Angela Branson Stephen Brearey Vicky Brocklebank Sharanjit Budwal Conor Byrne Hugh Cairns Brian Camilleri Gary Campbell A. Capell Margaret Carmody Marion Carson Tracy Cathcart Christine Catley Karine Cesar Melanie M. Y. Chan Houda Chea James Chess Chee Kay Cheung Katy-Jane Chick Nihil Chitalia Martin Christian Constantina Chrysochou Katherine Clark Christopher L. Clayton Rhian Clissold Helen Cockerill Joshua Coelho Elizabeth Colby Viv Colclough Eileen Conway H. Terence Cook Wendy L. Cook Theresa Cooper Richard J. Coward Sarah Crosbie Gabor Cserep Anjali Date

BackgroundIndividuals with rare kidney diseases account for 5–10% of people chronic disease, but constitute more than 25% patients receiving replacement therapy. The National Registry Rare Kidney Diseases (RaDaR) gathers longitudinal data from these conditions, which we used to study disease progression and outcomes death failure.MethodsPeople aged 0–96 years living 28 types were recruited 108 UK renal care facilities. primary cumulative incidence mortality failure in individuals diseases,...

10.1016/s0140-6736(23)02843-x article EN cc-by The Lancet 2024-03-01

The concept of regulatory T cell (Treg)-based immunotherapy has enormous potential for facilitating tolerance in autoimmunity and transplantation. Clinical translation Treg therapy requires production processes that satisfy the rigors Good Manufacturing Practice (GMP) standards. In this regard, we report our findings on implementation a robust GMP compliant process ex vivo expansion clinical grade Tregs, demonstrating feasibility developed manufacture final product application. This...

10.1016/j.omtm.2018.01.006 article EN cc-by Molecular Therapy — Methods & Clinical Development 2018-01-31

Short-term outcomes in kidney transplantation are marred by progressive transplant failure and mortality secondary to immunosuppression toxicity. Immune modulation with autologous polyclonal regulatory T cell (Treg) therapy may facilitate reduction promoting better long-term clinical outcomes. In a Phase I trial, 12 recipients received 1–10 × 106 Treg per kg at Day +5 posttransplantation lieu of induction (Treg Therapy cohort). Nineteen patients standard (Reference Primary were...

10.1111/ajt.16395 article EN cc-by-nc-nd American Journal of Transplantation 2020-11-10

We and others have previously described signatures of tolerance in kidney transplantation showing the differential expression B cell–related genes relative expansions cell subsets. However, all these studies, index group—namely, tolerant recipients—were not receiving immunosuppression (IS) treatment, unlike rest comparator groups. aimed to assess confounding effect regimens develop a novel IS-independent signature tolerance. Analyzing gene three independent transplant patient cohorts (232...

10.1111/ajt.13932 article EN cc-by American Journal of Transplantation 2016-06-21

Introduction Psychological distress is common in end-stage kidney disease (ESKD) and associated with poorer health outcomes. Cognitive behavioural therapy (CBT) recommended UK clinical guidelines for the management of depression people long-term conditions. Access to skilled therapists competent managing competing mental physical demands ESKD limited. Online CBT treatments tailored needs population offers a pragmatic solution under-resourced services. This study examines feasibility...

10.1136/bmjopen-2016-011286 article EN cc-by-nc BMJ Open 2016-04-01

The risk of COVID-19 infection in transplant recipients (TRs) is unknown. Patients on dialysis may be exposed to greater due an inability isolate. Consideration these competing risks important before restarting suspended programs. This study compared outcomes kidney and kidney/pancreas TRs with those the waiting list, following admission a high-prevalence region.Audit data from all 6 London centers were amalgamated. Demographic laboratory collected included mortality, intensive care (ITU)...

10.1097/tp.0000000000003533 article EN Transplantation 2020-11-13

There is accumulating evidence that cell surface molecules may be transferred between cells during an encounter. The aim of these experiments was to determine whether transfer allogeneic material T could influence human alloresponses. CD4(+) were cocultured with M1 (human fibroblast) transfectants expressing HLA-DR1, CD80 and CD86 alone or in combination. Up 95% the became positive for HLA-DR appropriate costimulatory after only 4 h coculture. phenomenon required contact membrane fluidity...

10.1111/j.1600-6143.2005.00916.x article EN cc-by-nc-nd American Journal of Transplantation 2005-06-08

Immunosuppressive drugs are essential for the prevention of acute transplant rejection but some may not promote long-term tolerance. Tolerance is dependent on presence and regulatory function CD4+CD25+ T cells in a number animal models. The direct effects immunosuppressive cells, particularly those that interfere with IL-2 signaling uncertain. We studied rapamycin derivative everolimus anti-CD25 monoclonal antibody basiliximab capacity human vitro. Both permitted suppression proliferation...

10.1111/j.1600-6143.2005.00758.x article EN cc-by-nc-nd American Journal of Transplantation 2005-03-01

Background. There are no clear guidelines on renal transplantation in patients with antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis. Methods. We undertook a survey of transplant centres across Europe to assess whether there was consensus about how manage then identified 107 allograft recipients whose primary disease systemic vasculitis and assessed their outcome post-transplant. Results. All questionnaire respondents felt that should be remission at transplantation, 16%...

10.1093/ndt/gfp347 article EN Nephrology Dialysis Transplantation 2009-07-13

CD4(+)CD25(+) and CD1d-restricted natural killer T (NKT) cells are thymus-derived self-reactive regulatory that play a key role in the control of pathological immune responses. Little is known about functional cooperation between innate NKT adaptive cells. Here we show human CD4(+)Valpha24(+)Vbeta11(+) (CD4(+) NKT) isolated from peripheral blood by flow cytometric cell sorting secrete substantial amounts IL-2 after stimulation with dendritic (DC) alpha-Galactosylceramide. When cocultured...

10.1002/eji.200425899 article EN European Journal of Immunology 2005-03-15

Harnessing naturally arising CD4+ CD25+ regulatory T cells (Tregs) for potential adoptive cell therapy is hampered by their innate autoreactivity and limited number.CD4+ Tregs were purified from peripheral blood of human leukocyte antigen (HLA) DR1*0101+ A2- individuals, stimulated with autologous monocyte-derived dendritic (DCs).Here we show that specific an HLA A2 (103-120) peptide can be selected the population a healthy individual detected using tetramer comprised DRB1*0101 peptide. The...

10.1097/01.tp.0000244932.29542.9e article EN Transplantation 2006-12-19

CD4(+)CD25(+) regulatory T cells have been shown to regulate a variety of autoimmune and allogeneic responses in mice humans. The role regulating alloresponses human transplant recipients remains uncertain. Previous research has demonstrated reduced frequency direct pathway donor-specific renal when compared with the reactive an HLA-matched third party. A number mechanisms proposed account for this finding; purpose study was determine whether play significant role. Twelve stable patients...

10.1097/01.asn.0000067411.03024.a9 article EN Journal of the American Society of Nephrology 2003-06-01

To estimate the proportion of psychiatric inpatients receiving primary interventions based on randomised controlled trials or systematic reviews trials.Retrospective survey.Acute adult general ward.All patients admitted to ward during a 28 day period.Primary were classified according whether not they supported by evidence from reviews.The received 26/40 (65%; 95% confidence interval (95% CI) 51% 79%) period reviews.When used as denominator, most given in acute psychiatry experimental...

10.1136/qshc.5.4.215 article EN BMJ Quality & Safety 1996-12-01

Higher blood pressures (mean systolic difference 16.8 mmHg) when compared to matched individuals are already reported in patients with calcium urolithiasis. We present the prevalence of hypertension and renal impairment cystinuria from our specialist single centre. analysed prospective database adult who attend service. This included details medical operative management their disease. Descriptive statistics were used analyse data. 120 a median age 40 (19–76) years, 66 male (55%) 54 female...

10.1007/s00240-019-01110-8 article EN cc-by Urolithiasis 2019-02-25

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and carries a fatality rate of 1.0% to 13.5% in confirmed cases.1Verity R. Okell L.C. Ddorigatti I. et al Estimates the severity 2019: model-based analysis.Lancet Infect Dis. 2020; 20: 669-677Abstract Full Text PDF PubMed Scopus (2298) Google Scholar,2Johns Hopkins University Center for Systems Science Engineering (JHU CSSE)COVID-19 Data Repository (CSSE) at Johns...

10.1016/j.ekir.2020.05.018 article EN cc-by-nc-nd Kidney International Reports 2020-05-28
Coming Soon ...